CD8A and neoplasm: Recently, [89Zr]crefmirlimab berdoxam PET-MRI has been used to provide data integrating CD8+ cell changes in both tumor lesions and lymphoid tissues, with changes in tumor cellularity as derived from diffusion-weighted MRI.